Showing results (51-60 of 439) with videos related to
Sort By:
Pageof 44
Drugs of Today (Barcelona, Spain : 1998)|October 28, 2022
Asciminib in chronic myeloid leukemiaGiovanni Manfredi Assanto, Emilia Scalzulli, Massimo BrecciaCurrent Opinion in Hematology|January 18, 2014
ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?Massimo Breccia, Laura Cicconi, Francesco Lo-CocoExpert Review of Hematology|April 28, 2015
Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?Massimo Breccia, Matteo Molica, Gioia Colafigli, et al.Expert Opinion on Investigational Drugs|June 16, 2021
Asciminib: an investigational agent for the treatment of chronic myeloid leukemiaMassimo Breccia, Gioia Colafigli, Emilia Scalzulli, et al.Blood Reviews|April 8, 2020
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?Emilia Scalzulli, Sara Pepe, Gioia Colafigli, et al.Expert Opinion on Drug Safety|January 23, 2016
Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemiaMassimo Breccia, Gioia Colafigli, Matteo Molica, et al.Expert Opinion on Pharmacotherapy|May 28, 2016
How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safetySalvatore Perrone, Fulvio Massaro, Giuliana Alimena, et al.British Journal of Haematology|August 31, 2019
A journey through infectious risk associated with ruxolitinibEmanuela Sant'Antonio, Massimiliano Bonifacio, Massimo Breccia, et al.Journal of Clinical Medicine|February 4, 2021
Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic ChallengeAlessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, et al.Expert Review of Hematology|March 10, 2018
Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacyFulvio Massaro, Gioia Colafigli, Matteo Molica, et al.Pageof 44